Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

CD79 Expression Is Associated with Cell-of-Origin and Outcome in Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1760.

https://doi.org/10.1182/blood-2023-172972

Published: 2023

Journal Articles

Alpha-Pinene As a Novel Therapeutic Agent for T-Cell Tumors

Masaya Abe, Noboru Asada, Maiko Kimura, Chie Fukui, Daisuke Yamada, Ziyi Wang, Masayuki Miyake, Takeshi Takarada, Mitsuaki Ono, Michinori Aoe, Wataru Kitamura, Masayuki Matsuda, Takashi Moriyama, Akifumi Matsumura, Yoshinobu Maeda

Blood (2023) 142 (Supplement 1): 1441.

https://doi.org/10.1182/blood-2023-181447

Published: 2023

Journal Articles

Single Cell Multi Omics and Spatial Analysis Reveals Plasmablast Signature Malignant Cells As a Key of Intratumor Heterogeneity in Primary Central Nervous System Lymphoma

Blood (2023) 142 (Supplement 1): 2998.

https://doi.org/10.1182/blood-2023-174410

Published: 2023

Journal Articles

Real-World Data in a Prospective Clinical Observation Study for Newly Diagnosed Adult Acute Lymphoblastic Leukemia, the JALSG ALL-CS-12 : Advanced Age Is a Poor Prognostic Factor

Yoshihiro Hatta, Fumihiko Hayakawa, Etsuko Yamazaki, Tohru Murayama, Takeshi Saito, Satoru Takada, Nobuaki Dobashi, Shuichi Ota, Yasuhisa Yokoyama, Masatsugu Tanaka, Shinya Sato, Shigeki Ohtake, Emiko Sakaida, Yoshinobu Maeda, Takahiro Yamauchi, Itaru Matsumura, Yasushi Miyazaki, Hitoshi Kiyoi

Blood (2023) 142 (Supplement 1): 4199.

https://doi.org/10.1182/blood-2023-178332

Published: 2023

Journal Articles

Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan

Blood (2022) 140 (Supplement 1): 6421–6423.

https://doi.org/10.1182/blood-2022-157702

Published: 2022

Journal Articles

Impact of the Dose of Post-Transplant Cyclophosphamide and the Start Timing of Tacrolimus in Patients Who Received Allogeneic Stem-Cell Transplantation from Haploidentical Donor

Toshiki Terao, Ken-ichi Matsuoka, Hiroki Takasuka, Takumi Kondo, Chihiro Kamoi, Hiroko Ueda, Akifumi Matsumura, Chisato Matsubara, Kaho Kondo, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Yoshinobu Maeda

Blood (2022) 140 (Supplement 1): 12867–12868.

https://doi.org/10.1182/blood-2022-166571

Published: 2022

Journal Articles

Influence of Oral Microbiota on Chronic Graft-Versus-Host Disease and Its Role As a Therapeutic Target

Yui Kambara, Hideaki Fujiwara, Akira Yamamoto, Mari Kunihiro, Tadashi Oyama, Takumi Kondo, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Nobuharu Fujii, Keiko Fujii, Ken-ichi Matsuoka, Yoshinobu Maeda

Blood (2022) 140 (Supplement 1): 10202–10203.

https://doi.org/10.1182/blood-2022-162323

Published: 2022

Journal Articles

Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML

Toshiki Terao, Ken-ichi Matsuoka, Hiroko Ueda, Akifumi Matsumura, Chisato Matsubara, Kaho Kondo, Takumi Kondo, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Yoshinobu Maeda

Blood (2022) 140 (Supplement 1): 3290–3291.

https://doi.org/10.1182/blood-2022-163876

Published: 2022

Journal Articles

ASXL1 Mutations Predict a Poor Response to Darbepoetin Alfa in Anemic Patients with Low-Risk MDS: A Multicenter, Phase II Study

Hitoshi Hanamoto, Yasuyoshi Morita, Motoshi Ichikawa, Yasuhito Nannya, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD, Tomoko Hata, Toshihiro Miyamoto, MD PhD, Hiroshi Kawabata, MD PhD, Kazuto Takeuchi, Hiroko Tanaka, Junji Kishimoto, Satoru Miyano, PhD, Itaru Matsumura, MDPhD, Seishi Ogawa, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD, Kinuko Mitani

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134483

Published: 2020

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Yukio Kobayashi, Iekuni Oh, MD PhD, Toshihiro Miyamoto, MD PhD, Won-Sik Lee, Hiroatsu Iida, MD PhD, Hironobu Minami, MD PhD, Yoshinobu Maeda, MD PhD, Jun Ho Jang, Sung-Soo Yoon, MD PhD, Su-Peng Yeh, MD, Qui Tran, Joan Morris, Janet L. Franklin, Ka-Wing Chong, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 5069.

https://doi.org/10.1182/blood-2019-124582

Published: 2019

Journal Articles

Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (r/r AITL) North Asian Patients after Failure of First-Line Therapy: A Pooled Analysis of Two Pralatrexate Studies

Jun Zhu, MD, Ee-Min Yeoh, BSc, Yoshinobu Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 5290.

https://doi.org/10.1182/blood-2019-124080

Published: 2019

Journal Articles

Mechanistic Analysis of Prolonged Negative Impacts of Anti-CCR4 Antibody Mogamulizumab on Regulatory T Cell Homeostasis after Allogeneic Hematopoietic Stem Cell Transplantation

Yasuhisa Sando, MD, Ken-Ichi Matsuoka, MD PhD, Yusuke Meguri, MD, Takumi Kondo, MD, Shuntaro Ikegawa, MD, Hiroyuki Sugiura, MD, Makoto Nakamura, MD, Miki Iwamoto, Takeru Asano, Takanori Yoshioka, MD, Yoshinobu Maeda, MD PhD

Blood (2018) 132 (Supplement 1): 3400.

https://doi.org/10.1182/blood-2018-99-117548

Published: 2018

Journal Articles

Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Yukio Kobayashi, MD DSc, Zachary F. Zimmerman, Iekuni Oh, MD PhD, Yoshinobu Maeda, MD PhD, Hironobu Minami, MD PhD, Toshihiro Miyamoto, MD PhD, Toru Sakura, PhD MD, Hiroatsu Iida, MD PhD, Yuqi Chen, PhD, Hitoshi Kiyoi, MD PhD

Blood (2018) 132 (Supplement 1): 5167.

https://doi.org/10.1182/blood-2018-99-112584

Published: 2018

Journal Articles

Posttransplant Cyclophosphamide Promote Naïve-Subset Dominant B Cell Recovery Coordinated with Early Treg Expansion; Implication of Reduced Risk of Pathogenesis into Chronic Gvhd

Miki Iwamoto, Yusuke Meguri, MD, Takumi Kondo, MD, Hiroyuki Sugiura, MD, Shuntaro Ikegawa, MD, Yasuhisa Sando, MD, Makoto Nakamura, MD, Yoshinobu Maeda, MD PhD, Ken-Ichi Matsuoka, MD PhD

Blood (2018) 132 (Supplement 1): 4566.

https://doi.org/10.1182/blood-2018-99-120081

Published: 2018

Journal Articles

Who Is the Best Donor for the Second Transplant?: HLA Discrepancy between Graft and Host Rather Than That Graft and First Donor May Impact the Second Transplant Outcome from the JSHCT

Yoshinobu Maeda, MD PhD, Tomotaka Ugai, MD, Eisei Kondo, Kazuhiro Ikegame, MD PhD, Makoto Murata, MD PhD, Naoyuki Uchida, MD PhD, Toshihiro Miyamoto, MD PhD, Satoshi Takahashi, MD PhD, Kazuteru Ohashi, MD PhD, Hirohisa Nakamae, MD PhD, Makoto Hirokawa, MD PhD, Tatsuo Ichinohe, MD PhD, Yoshiko Atsuta, MD PhD, Yoshinobu Kanda, MD PhD, Junya Kanda, MD

Blood (2018) 132 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2018-99-112796

Published: 2018

Journal Articles

Post-Transplant Cyclophosphamide Ameliorates Lethal Thymic GVHD By Restoring Regulatory and Effector T Cell Homeostasis in Recipients with Prior PD-1 Blockade Therapy

Shuntaro Ikegawa, MD, Yusuke Meguri, MD, Takumi Kondo, MD, Hiroyuki Sugiura, MD, Yasuhisa Sando, MD, Makoto Nakamura, MD, Miki Iwamoto, Yoshinobu Maeda, MD PhD, Ken-Ichi Matsuoka, MD PhD

Blood (2018) 132 (Supplement 1): 479.

https://doi.org/10.1182/blood-2018-99-111142

Published: 2018

Journal Articles

Efficacy of HLA-Matched PLT Transfusions for Platelet Transfusion Refractoriness in HSCT Patients

Keisuke Seike, Nobuharu Fujii, MD PhD, Keiko Fujii, MD PhD, Yasuhisa Sando, MD, Makoto Nakamura, MD, Kyosuke Saeki, MD, Yusuke Meguri, MD, Noboru Asada, MD PhD, Daisuke Ennishi, MDPhD, Hisakazu Nishimori, MD PhD, Ken-Ichi Matsuoka, MD PhD, Yoshinobu Maeda, MDPhD

Blood (2018) 132 (Supplement 1): 1265.

https://doi.org/10.1182/blood-2018-99-112365

Published: 2018

Journal Articles

CD56 Is an Unfavorable Prognostic Factor for Acute Promyelocytic Leukemia: Results By Multivariate Analyses in the JALSG-APL204 Study

Blood (2018) 132 (Supplement 1): 2798.

https://doi.org/10.1182/blood-2018-99-111638

Published: 2018

Journal Articles

Updated Report of a Phase I/II Multicenter Study of Forodesine, a Purine Nucleoside Phosphorylase Inhibitor, in Japanese Patients with Relapsed Peripheral T-Cell Lymphoma

Blood (2017) 130 (Supplement 1): 4075.

https://doi.org/10.1182/blood.V130.Suppl_1.4075.4075

Published: 2017

NARROW

CD79 Expression Is Associated with Cell-of-Origin and Outcome in Diffuse Large B-Cell Lymphoma

Alpha-Pinene As a Novel Therapeutic Agent for T-Cell Tumors

Single Cell Multi Omics and Spatial Analysis Reveals Plasmablast Signature Malignant Cells As a Key of Intratumor Heterogeneity in Primary Central Nervous System Lymphoma

Real-World Data in a Prospective Clinical Observation Study for Newly Diagnosed Adult Acute Lymphoblastic Leukemia, the JALSG ALL-CS-12 : Advanced Age Is a Poor Prognostic Factor

Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan

Impact of the Dose of Post-Transplant Cyclophosphamide and the Start Timing of Tacrolimus in Patients Who Received Allogeneic Stem-Cell Transplantation from Haploidentical Donor

Influence of Oral Microbiota on Chronic Graft-Versus-Host Disease and Its Role As a Therapeutic Target

Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML

ASXL1 Mutations Predict a Poor Response to Darbepoetin Alfa in Anemic Patients with Low-Risk MDS: A Multicenter, Phase II Study

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (r/r AITL) North Asian Patients after Failure of First-Line Therapy: A Pooled Analysis of Two Pralatrexate Studies

Mechanistic Analysis of Prolonged Negative Impacts of Anti-CCR4 Antibody Mogamulizumab on Regulatory T Cell Homeostasis after Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Posttransplant Cyclophosphamide Promote Naïve-Subset Dominant B Cell Recovery Coordinated with Early Treg Expansion; Implication of Reduced Risk of Pathogenesis into Chronic Gvhd

Who Is the Best Donor for the Second Transplant?: HLA Discrepancy between Graft and Host Rather Than That Graft and First Donor May Impact the Second Transplant Outcome from the JSHCT

Post-Transplant Cyclophosphamide Ameliorates Lethal Thymic GVHD By Restoring Regulatory and Effector T Cell Homeostasis in Recipients with Prior PD-1 Blockade Therapy

Efficacy of HLA-Matched PLT Transfusions for Platelet Transfusion Refractoriness in HSCT Patients

CD56 Is an Unfavorable Prognostic Factor for Acute Promyelocytic Leukemia: Results By Multivariate Analyses in the JALSG-APL204 Study

Updated Report of a Phase I/II Multicenter Study of Forodesine, a Purine Nucleoside Phosphorylase Inhibitor, in Japanese Patients with Relapsed Peripheral T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only